Comparative Pharmacology
Head-to-head clinical analysis: CEFIZOX IN DEXTROSE 5 IN PLASTIC CONTAINER versus CEFOXITIN IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CEFIZOX IN DEXTROSE 5 IN PLASTIC CONTAINER versus CEFOXITIN IN PLASTIC CONTAINER.
CEFIZOX IN DEXTROSE 5% IN PLASTIC CONTAINER vs CEFOXITIN IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ceftizoxime is a third-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), leading to cell lysis and death. It has broad-spectrum activity against gram-positive and gram-negative bacteria.
Cefoxitin inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), specifically PBP1a, PBP1b, and PBP2, thereby inhibiting transpeptidation and leading to cell lysis. It is a cephamycin antibiotic resistant to beta-lactamase hydrolysis due to a 7-alpha-methoxy group.
1-2 g IV every 8-12 hours; maximum 12 g/day
1-2 g IV every 6-8 hours; maximum 12 g/day
None Documented
None Documented
1.5–2 hours in normal renal function; extends to 20–30 hours in ESRD. Dose adjustment required for CrCl <50 mL/min.
Terminal elimination half-life: 0.7-1.5 hours (approximately 45-90 minutes); prolonged to 2-6 hours in moderate renal impairment (CrCl 30-50 mL/min) and up to 10-20 hours in severe renal impairment (CrCl <10 mL/min).
Renal: 80–90% unchanged via glomerular filtration and tubular secretion. Biliary/fecal: <10%.
Renal: 85-95% unchanged via glomerular filtration and tubular secretion; biliary: <2%; fecal: trace.
Category C
Category A/B
Cephalosporin Antibiotic
Cephalosporin Antibiotic